ADMA BIOLOGICS, INC.ADMAEarnings & Financial Report
Nasdaq · Health Care · Biological Products, (No Diagnostic Substances)
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 16.40% | 38.3M | ▲ +8.50pp | 2024-10-07 |
| The Vanguard Group | 7.77% | 18.1M | flat | 2024-11-12 |
| STATE STREET CORPORATION | 5.60% | 13.0M | — | 2024-10-17 |
| OF ABOVE PERSONS | 5.50% | 12.8M | — | 2024-11-08 |
| Perceptive Advisors LLC | 2.80% | 6.4M | — | 2024-02-14 |
| Nuveen Asset Management, LLC | 2.17% | 5.0M | flat | 2024-03-11 |
| Millennium Management LLC | 0.60% | 1.4M | — | 2024-09-23 |
Insider Transactions
Net 90d: −$596.4K · buys $217.4K / sells $813.8KRange:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-03-17 | Guiheen Lawrence P. | Director | Gift | 30.0K | $0.00 | $0 |
| 2026-03-17 | Guiheen Lawrence P. | Director | Gift | 30.0K | $0.00 | $0 |
| 2026-03-16 | Grossman Adam S | President and CEO | Option exercise | 15.0K | $5.40 | $81.0K |
| 2026-03-16 | Grossman Adam S | President and CEO | Sell (open market) | 15.0K | $15.16 | $227.4K |
| 2026-03-16 | Grossman Adam S | President and CEO | Sell (open market) | 6.0K | $15.16 | $91.0K |
| 2026-03-13 | Guiheen Lawrence P. | Director | Option exercise | 30.0K | $3.66 | $109.8K |
| 2026-03-09 | Kestenberg-Messina Kaitlin M. | COO and SVP, Compliance | Other | 91.3K | $0.00 | $0 |
| 2026-03-09 | Kestenberg-Messina Kaitlin M. | COO and SVP, Compliance | Option exercise | 2.5K | $5.00 | $12.5K |
| 2026-03-09 | Kestenberg-Messina Kaitlin M. | COO and SVP, Compliance | Option exercise | 1.3K | $4.31 | $5.4K |
| 2026-03-09 | Kestenberg-Messina Kaitlin M. | COO and SVP, Compliance | Option exercise | 2.6K | $2.83 | $7.5K |
1–10 of 26
Page 1 / 3